系统性硬化症合并间质性肺病患者纤维化范围与肺功能下降:SENSCIS 试验数据
基于 SENSCIS 试验,采用广义可加模型分析 288 例安慰剂组和 288 例尼达尼布组患者基线纤维化间质性肺病范围与 52 周内用力肺活量变化的关系。安慰剂组基线纤维化范围与 FVC 占预计值百分比下降之间仅有微弱证据提示轻度关联(r=-0.09,95%CI -0.2, 0.03),尼达尼布组无关联证据(r=0.01,95%CI -0.11, 0.12)。结论提示 SSc-ILD 患者无论基线纤维化范围如何均有 ILD 进展风险,且大多可从尼达尼布获益。
要点
- 安慰剂组基线纤维化范围与 52 周 FVC 占预计值百分比下降仅微弱关联(r=-0.09,95%CI -0.2, 0.03)。
- 尼达尼布组基线纤维化范围与 52 周 FVC 占预计值百分比下降无关联证据(r=0.01,95%CI -0.11, 0.12)。
- SENSCIS 试验数据提示 SSc-ILD 患者无论基线纤维化范围如何均有 ILD 进展风险,且大多可从尼达尼布获益。
核心结论
- SENSCIS 试验数据提示 SSc-ILD 患者存在 ILD 进展风险,且大多可从尼达尼布获益,与基线纤维化 ILD 范围关系不大。
研究设计与样本
- 基于 SENSCIS 试验,采用广义可加模型评估基线 HRCT 纤维化 ILD 范围与 52 周 FVC 变化的关系,安慰剂组 n=288,尼达尼布组 n=288。
主要发现
- 安慰剂组基线纤维化 ILD 范围更大与 52 周 FVC 占预计值百分比下降更多之间仅有微弱证据提示轻度关联(r=-0.09,95%CI -0.2, 0.03)。
- 安慰剂组基线纤维化 ILD 范围和 FVC 占预计值百分比均较高时,52 周 FVC 占预计值百分比下降趋于更大。
- 尼达尼布组基线纤维化 ILD 范围与 52 周 FVC 占预计值百分比下降无关联证据(r=0.01,95%CI -0.11, 0.12)。
- 尼达尼布组基线纤维化 ILD 范围与 FVC 占预计值百分比的交互作用与 52 周 FVC 占预计值百分比下降之间无关联证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess associations between the extent of fibrotic interstitial lung disease (ILD) and forced vital capacity (FVC) at baseline and change in FVC over 52 weeks in patients with systemic sclerosis-associated ILD (SSc-ILD) in the SENSCIS trial. MATERIAL AND METHODS: We used generalized additive models, which involve few assumptions and allow for interaction between non-linear effects, to assess associations between the extent of fibrotic ILD on high-resolution computed tomography (HRCT), and the interplay of extent of fibrotic ILD on HRCT and FVC % predicted, at baseline and FVC decline over 52 weeks. RESULTS: In the placebo group (n = 288), there was weak evidence of a modest association between a greater extent of fibrotic ILD at baseline and a greater decline in FVC % predicted at week 52 [r: -0.09 (95% CI -0.2, 0.03)]. Higher values of both the extent of fibrotic ILD and FVC % predicted at baseline tended to be associated with greater decline in FVC % predicted at week 52. In the nintedanib group (n = 288), there was no evidence of an association between the extent of fibrotic ILD at baseline and decline in FVC % predicted at week 52 [r: 0.01 (95% CI: -0.11, 0.12)] or between the interplay of extent of fibrotic ILD and FVC % predicted at baseline and decline in FVC % predicted at week 52. CONCLUSIONS: Data from the SENSCIS trial suggest that patients with SSc-ILD are at risk of ILD progression and benefit from nintedanib largely irrespective of their extent of fibrotic ILD at baseline. STUDY REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02597933.
引用
- Denton CP, Goh NS, Humphries SM, et al. Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial. Rheumatology (Oxford). 2023. PMID: 36111858. doi:10.1093/rheumatology/keac535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。